Application of minimal residual disease testing in assessing response to treatment of AML

At the 2019 ASCO Annual Meeting in Chicago, US, Michael Heuser from Hannover Medical School, Hannover, DE, discusses MRD testing and its application to AML patients during treatment and after treatment, to assess the response of patients. There are recommendations out by the NCCN and the European Leukemia Network (ELN), that recommend sequences at how to look at MRD. Dr. Heuser explains how we should first look at molecular abrasions like MPN1 and fusion oncogenes and apply quantitive real-time polymerase chain reaction (PCR) for MRD assessment; if none of these abrasions are present using multicolor flow cytometry if there is leukemia associated phenotype that can be investigated.